TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2201794

Group type: EXPERIMENTAL
Intervention: Topical low dose heparin (0.125 gm./l., 25,000 units per l.)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Glycine solution alone (control)
Number of subjects: 70
Study: 7299385

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 39
Study: 31130666

Group type: EXPERIMENTAL
Intervention: KP extract 90 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KP extract 180 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29482225

Group type: EXPERIMENTAL
Intervention: Intervention group (shared decision support intervention)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 248
Study: 26791430

Group type: EXPERIMENTAL
Intervention: New format of summary of findings (SoF) tables
Number of subjects: 290

Group type: COMPARATOR
Intervention: Current format of summary of findings (SoF) tables
Number of subjects: 290
Study: 24627207

Group type: EXPERIMENTAL
Intervention: 2 mg intraventricular tissue plasminogen activator (TPA) every 12 h (maximum 10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22526147

Group type: EXPERIMENTAL
Intervention: Exercise training (individualized, high-intensity aerobic interval training)
Number of subjects: 24
Study: 20022598

Group type: EXPERIMENTAL
Intervention: Top-hat LEEP
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional LEEP
Number of subjects: 180
Study: 18591524

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 16630999

Group type: EXPERIMENTAL
Intervention: lixivaptan 10, 30, 75, 150, 250, or 400 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: lixivaptan (higher doses)
Number of subjects: 42
Study: 11972383

Group type: EXPERIMENTAL
Intervention: Media recruitment strategy
Number of subjects: 2583

Group type: COMPARATOR
Intervention: Clinic registry recruitment
Number of subjects: 2583
Study: 10577530

Group type: EXPERIMENTAL
Intervention: Photocoagulation and aspirin treatment
Number of subjects: 2701

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 2701
Study: 8561333

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA) with 5 mg of 0.5% hyperbaric bupivacaine, followed by optional reinjection of 2.5 mg every 5 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia (SDSA) with 10-15 mg of 0.5% hyperbaric bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-dose spinal anesthesia (SDSA)
Number of subjects: 60
Study: 2008876

Group type: EXPERIMENTAL
Intervention: 4-6 140-mL cups filtered decaffeinated coffee per day and 75 mg caffeine pills
Number of subjects: 69

Group type: COMPARATOR
Intervention: 4-6 140-mL cups filtered decaffeinated coffee per day and placebo pills
Number of subjects: 69
Study: 6351333

Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous diazepam (10 mg) after intramuscular atropine (0.6 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control) after intramuscular atropine (0.6 mg)
Number of subjects: 60
Study: 29401529

Group type: EXPERIMENTAL
Intervention: Tissue flossing (3 treatments lasting 2 minutes each)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tissue flossing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no tissue flossing)
Number of subjects: 42
Study: 29231589

Group type: EXPERIMENTAL
Intervention: Moxibustion at Shenshu (BL 23) for 15 min, once a day, for 4 courses with 2 days interval between courses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of soft capsule of Vitamin E, once a day for 28 days
Number of subjects: 60
Study: 25660952

Group type: EXPERIMENTAL
Intervention: AHA-R (American Heart Association recommendation)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: ERC-R (European Resuscitation Council recommendation)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: AHA-R
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: ERC-R
Number of subjects: 220
Study: 23325537

Group type: EXPERIMENTAL
Intervention: Thought-shape fusion (TSF) induction
Number of subjects: 82

Group type: COMPARATOR
Intervention: Neutral induction
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 82
Study: 20921239

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 54
Study: 18719752

Group type: EXPERIMENTAL
Intervention: Trained group (physical exercise program including aerobic training, muscle strength training, agility and joint flexibility activities)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untrained group (no exercise program)
Number of subjects: 42
Study: 17015814

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide (4 microg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14617718

Group type: EXPERIMENTAL
Intervention: acetylcholinesterase inhibitor (donepezil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 11933449

Group type: EXPERIMENTAL
Intervention: Visco-elastic foam mattress
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard mattress
Number of subjects: 101
Study: 9039344

Group type: EXPERIMENTAL
Intervention: Growth hormone (up to 0.25 U/kg/week in daily doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8249050

Group type: EXPERIMENTAL
Intervention: Nicotine skin patches (three different doses applied to different groups)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Saliva collection methods (sucking on a lemon candy, dissolving a sugar cube in the mouth, chewing on parafilm)
Number of subjects: 24
Study: 2861526

Group type: EXPERIMENTAL
Intervention: Spectacles with left lens occluded
Number of subjects: 148

Group type: COMPARATOR
Intervention: Plain spectacles (untreated)
Number of subjects: 148
Study: 31399431

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes genetic risk score (comprising 48 established risk variants)
Number of subjects: 160000
Study: 28857223

Group type: EXPERIMENTAL
Intervention: Perceptual support for accurately encoding the equal sign
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (feedback only)
Number of subjects: 0
Study: 26757793

Group type: EXPERIMENTAL
Intervention: High-flavonoid (HF) intake with increased F&V by 2, 4, and 6 portions for 6 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Low-flavonoid (LF) intake with increased F&V by 2, 4, and 6 portions for 6 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group with habitual diet
Number of subjects: 122
Study: 25864712

Group type: EXPERIMENTAL
Intervention: Challenge-proven cow's milk allergy (CMA)
Number of subjects: 12049

Group type: EXPERIMENTAL
Intervention: Re-evaluation of children with CMA after one year
Number of subjects: 12049
Study: 23012270

Group type: EXPERIMENTAL
Intervention: Duchenne smile
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Standard smile
Number of subjects: 170

Group type: COMPARATOR
Intervention: Neutral expression
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Duchenne smile (not explicitly asked to smile)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Standard smile (not explicitly asked to smile)
Number of subjects: 170
Study: 20436440

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cavinton
Number of subjects: 110
Study: 18543837

Group type: EXPERIMENTAL
Intervention: Breastfeeding educational program (5 sessions during hospitalization and after discharge)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Breastfeeding educational program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 60
Study: 15759073

Group type: EXPERIMENTAL
Intervention: Patients' beliefs about pain management
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Providers' pain management practices
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Patients with recent moderate to severe pain
Number of subjects: 342
Study: 12490345

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study: 10406622

Group type: EXPERIMENTAL
Intervention: Ab-interno goniotrabeculotomy (AIGT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mitomycin C trabeculectomy (MT)
Number of subjects: 32
Study: 7734261

Group type: EXPERIMENTAL
Intervention: Forced warm air convective heating blanket
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electric under mattress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warm air under mattress
Number of subjects: 0
Study: 1916494

Group type: EXPERIMENTAL
Intervention: Metronidazole 20 mg/kg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Metronidazole 10 mg/kg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Metronidazole (combined 20 mg/kg and 10 mg/kg)
Number of subjects: 105
Study: 393035

Group type: EXPERIMENTAL
Intervention: Oral retinoid (25 mg three times a day for six weeks)
Number of subjects: 0
Study: 30514775

Group type: EXPERIMENTAL
Intervention: DC–CIK combined with S‐1 plus cisplatin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DC–CIK combined with S‐1
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: S‐1 alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DC–CIK infusions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Decreased ctDNA mutational frequency and restored TCR repertoire
Number of subjects: 63
Study: 26197987

Group type: EXPERIMENTAL
Intervention: Patient admission protocol (experimental group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine admittance (control group)
Number of subjects: 100
Study: 25464161

Group type: EXPERIMENTAL
Intervention: Administrator survey evaluating organizational safety structures and processes
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Staff survey querying safety and communication concerns
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Referral and test result management systems
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: MD/PA/NPs perceptions of high-risk system reliability
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: MD/PA/NPs perceptions of teamwork
Number of subjects: 507
Study: 22855271

Group type: COMPARATOR
Intervention: Vardenafil (0.3-3 mg/kg) in rats; administered orally 30 min before testing.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vardenafil (10-20 mg) in humans; administered 85 min before testing.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in humans; administered 85 min before testing.
Number of subjects: 0
Study: 16909130

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity intervention
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study: 15609487

Group type: EXPERIMENTAL
Intervention: Manipulation intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Stabilization intervention
Number of subjects: 131
Study: 10871150

Group type: EXPERIMENTAL
Intervention: CSP/MTX/PSE
Number of subjects: 186

Group type: COMPARATOR
Intervention: CSP/MTX
Number of subjects: 186
Study: 9093656

Group type: EXPERIMENTAL
Intervention: Questionnaire assessment of occupational activities
Number of subjects: 152
Study: 8210543

Group type: EXPERIMENTAL
Intervention: Thymopentin 50 mg s.c. every other day, after irradiation for at least 6 cycles of 4 weeks each
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1060
Study: 3740202

Group type: EXPERIMENTAL
Intervention: Inhibitive ankle-foot orthoses
Number of subjects: 1
Study: 29947729

Group type: EXPERIMENTAL
Intervention: High-emotion pictorial warnings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-emotion pictorial warnings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 0
Study: 28293470

Group type: EXPERIMENTAL
Intervention: ABT‐436 800 mg QD
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 26430826

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (2 capsules/day for 8 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (2 capsules/day for 8 weeks)
Number of subjects: 42
Study: 24215730

Group type: EXPERIMENTAL
Intervention: PocketCPR
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CPRmeter
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: iPhone app PocketCPR
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard BLS
Number of subjects: 240
Study: 21830124

Group type: EXPERIMENTAL
Intervention: Chemotherapeutics plus verapamil infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Targeted intra-arterial infusion (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Verapamil infusion
Number of subjects: 100
Study: 19219314

Group type: EXPERIMENTAL
Intervention: Radial shockwave treatment (three applications, once a week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional physiotherapy (10 sessions of ultrasound, kinesiotherapy, and stretching instruction)
Number of subjects: 32
Study: 17309575

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride (MID) at 4 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: L-threo-3,4-dihydroxyphenylserine (L-DOPS) at 400 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 13
Study: 15112344

Group type: EXPERIMENTAL
Intervention: rhGH+PN group
Number of subjects: 24

Group type: COMPARATOR
Intervention: PN group
Number of subjects: 24
Study: 12378829

Group type: EXPERIMENTAL
Intervention: PTH 1-34
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strontium salt (oral administration at low dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose intermittent fluoride therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I and other growth factors
Number of subjects: 0
Study: 9660327

Group type: EXPERIMENTAL
Intervention: Low dose ethanol (LD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High dose ethanol (HD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 50
Study: 7665724

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (cumulative dose of 96 mg/m2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 20
Study: 2501110

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) Buserelin (300 micrograms three times a day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcutaneous (SC) Buserelin implant (6.6 mg Buserelin)
Number of subjects: 100
Study: 782796

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (400 mug daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 32
Study: 31633896

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study: 28218552

Group type: EXPERIMENTAL
Intervention: Arm A (newly-defined common technique for palatal repair)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Arms C or D (traditional local protocols)
Number of subjects: 448
Study: 26039125

Group type: EXPERIMENTAL
Intervention: Low intensity lifestyle modification (LILM) program for 6 months, including 4 interactive group discussion sessions and weekly phone contact with volunteer counselors.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninteractive session on diet and physical activity (comparison group).
Number of subjects: 0
Study: 23344468

Group type: EXPERIMENTAL
Intervention: Single dose prednisolone (1 mg/Kg/dose 24 h before surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5-day prednisolone (1 mg/Kg/day before operation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Surgeons' opinion about surgery field quality
Number of subjects: 80
Study: 20715901

Group type: EXPERIMENTAL
Intervention: Sourdough prepared with LV4 starter (Lactobacillus brevis combined with Saccharomyces cerevisiae var. chevalieri)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sourdough prepared with PL1 starter (Lactobacillus fermentum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sourdough prepared with PL3 starter (Lactobacillus fermentum with phytase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sourdough prepared with L. plantarum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bread without sourdough
Number of subjects: 0
Study: 19258723

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 70
Study: 17081831

Group type: EXPERIMENTAL
Intervention: Universal-free school breakfast offered in treatment schools for three consecutive school years (2000-2001 to 2002-2003)
Number of subjects: 4358

Group type: COMPARATOR
Intervention: Traditional means-tested School Breakfast Program in control schools
Number of subjects: 4358
Study: 15466731

Group type: EXPERIMENTAL
Intervention: Electrohydraulic high-energy shock waves treatment
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 364
Study: 11304780

Group type: EXPERIMENTAL
Intervention: Local excision alone
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Poorly differentiated DCIS
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Young age (<= 40 years)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Symptomatic detection of DCIS
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Growth pattern (solid and cribriform)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Involved margins
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Histologic type of DCIS
Number of subjects: 1010
Study: 9165360

Group type: EXPERIMENTAL
Intervention: Bifurcated e PTFE graft with stretch properties
Number of subjects: 14

Group type: COMPARATOR
Intervention: Collagen coated Dacron graft
Number of subjects: 14
Study: 7970842

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg p.o. daily for 7 days pre-operatively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3315282

Group type: EXPERIMENTAL
Intervention: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) 10-55 mg/m2 administered by i.v. bolus injection daily for acute leukemia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) administered according to three different schedules for malignant lymphoma: daily, weekly or once every 3-4 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: (2"R)-4'-O-tetrahydropyranyladriamycin (THP)
Number of subjects: 84
Study: 29228206

Group type: EXPERIMENTAL
Intervention: Early treatment group (n = 33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Late treatment group (n = 34)
Number of subjects: 67
Study: 27927951

Group type: EXPERIMENTAL
Intervention: 100 mg S44819
Number of subjects: 18

Group type: COMPARATOR
Intervention: 50 mg S44819
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24656054

Group type: EXPERIMENTAL
Intervention: CRAFT-T
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CRAFT-T (when CSO was parental family)
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 52
Study: 21887710

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (1,500 Units, 2,500 Units, or 3,500 Units)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 21109115

Group type: EXPERIMENTAL
Intervention: β-blocker treatment initiated >1 to 4 weeks before surgery
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: β-blocker treatment initiated >4 weeks before surgery
Number of subjects: 940

Group type: COMPARATOR
Intervention: β-blocker treatment initiated <1 week before surgery
Number of subjects: 940
Study: 17511802

Group type: EXPERIMENTAL
Intervention: Chemotherapy every 4 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Chemotherapy every 3 weeks (cisplatin-paclitaxel or carboplatin-paclitaxel)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Early-stage disease (chemotherapy every 4 weeks)
Number of subjects: 171
Study: 15910869

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Number of subjects: 324
Study: 12714865

Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg o.d.
Number of subjects: 27

Group type: COMPARATOR
Intervention: losartan 50 mg o.d.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg o.d. (responders only)
Number of subjects: 27

Group type: COMPARATOR
Intervention: losartan 50 mg o.d. (responders only)
Number of subjects: 27
Study: 11127443

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8652784

Group type: EXPERIMENTAL
Intervention: Intelligent control system for insulin dosage recommendations
Number of subjects: 42

Group type: COMPARATOR
Intervention: Diabetes specialists' recommendations
Number of subjects: 42
Study: 1294382

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (women)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (men)
Number of subjects: 152
Study: 6238315

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg administered intravenously
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ketoprofen 100 mg associated with noramidopyrine
Number of subjects: 62